Panbela Therapeutics Inc (PBLA) Return on Assets ROA from the third quarter of 2024 to third quarter of 2023 and for the year 2024, Average High and Low, Fundamental Ratios from Sep 30 2024 to Sep 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Panbela Therapeutics Inc   (PBLA)


Panbela Therapeutics Inc 's ROA from the third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Panbela Therapeutics Inc 's ROA in the third quarter of 2024?
Panbela Therapeutics Inc recorded a cumulative net loss of $-28 million during 12 months ending in the third quarter of 2024, resulting in a negative return on assets (ROA) of -308.74%.

However, within the Healthcare sector 976 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2024 quarter, so far to 4940, from total ROA ranking in the second quarter of 2024 at 4973.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter
Y / Y Total Assets Change -51.37 % -51.85 % -36.1 % 131.53 % 123 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -28 -29 -27 -25 -24
Return On Assets (TTM) -308.74 % -274.58 % -210.72 % -175.09 % -182.86 %
PBLA's Total Ranking # 4940 # 4973 # 4972 # 5675 # 5139
Total Assets (TTM) in million 5 9 11 11 11
Seq. Total Assets Change -45.1 % -10.57 % -4.82 % 4.06 % -45.64 %
Seq. Net Income Change - - - - -

PBLA's 5 Years Annual ROA >> Back to PBLA Management Effectiveness >> Compare PBLA ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 476
Sector # 977
Overall # 4841

Return On Assets Statistics
High Average Low
-28.04 %
-318.82 %
-1068.72 %
(Dec 31 2014)   (Jun 30 2015)



  News about Panbela Therapeutics Inc Return on Assets ROA

Panbela Pioneers First Patient Enrolled in STK11 Mutant NSCLC Phase I Trial at Moffitt Cancer Center,

In a significant stride towards addressing an urgent unmet medical need, Panbela Therapeutics, Inc. (OTCQB: PBLA) has announced the enrollment of the first patient in its Phase I dose escalation study aimed at treating STK11 mutant non-small cell lung cancer (NSCLC). The study is being conducted at the renowned Moffitt Cancer Center, a hub for leading oncological research. Deciphering the FactsAt the core of this groundbreaking initiative is CPP-1X-S (eflornithine sachets), an innovative therapeutic developed by Panbela Therapeutics. The aim of the Phase I trial is to identify the maximum tolerated dose of eflornithine when used in conjunction with Keytruda, an already established immune checkpoint inhibitor.



Financial Statements
Panbela Therapeutics Inc 's Assets $ 5 million PBLA's Balance sheet
Panbela Therapeutics Inc 's Income $ -7 million Quarterly PBLA's Income Statement
PBLA's Income by Division See PBLA's Income by Division



Annual Return On Assets (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019
Y / Y Total Assets Change 131.53 % -62.89 % 31.17 % 212.12 % 65.65 %
Total Assets in million 11 5 13 10 3
Y / Y Net Income Change - - - - -
Net Income in million -25 -35 -10 -5 -6
Annual Return On Assets -228.42 % -731.27 % -78.74 % -48.59 % -197.2 %

PBLA's 5 Years Annual ROA >> Back to PBLA Management Effectiveness >> Compare PBLA ROA to its Competitors



More Return On Assets Ratios
PBLA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PBLA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PBLA's Competitors
Subscribers only: Roa for Panbela Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for PBLA's Customers

You may also want to know
PBLA's Roi PBLA's Inventory Turnover Ratio PBLA's Growth Rates PBLA's Dividend Comparisons
PBLA's Profitability Ratios PBLA's Asset Turnover Ratio PBLA's Dividend Growth
PBLA's Roe PBLA's Valuation Ratios PBLA's Financial Strength Ratios PBLA's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2024, within Healthcare Sector ROA

Date modified: 2026-09-12T06:13:08+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.